Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Endometrial Neoplasms × Imlunestrant × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1 Breast 1

Conditions

Breast Neoplasms 4 Endometrial Neoplasms 1

Interventions

pembrolizumab 20 Paclitaxel 13 Carboplatin 13 temsirolimus 6 Trastuzumab 6 Taxes 6 Radiotherapy 5 Topotecan 4 Specimen Handling 4 Nivolumab 4 Magnetic Resonance Spectroscopy 4 Ipilimumab 4 Docetaxel 4 Cisplatin 4 Biopsy 4 Bevacizumab 4 lenvatinib 3 dostarlimab 3 atezolizumab 3 Sirolimus 3 Pemetrexed 3 Irinotecan 3 Gemcitabine 3 Fulvestrant 3 Cetuximab 3 spartalizumab 2 olaparib 2 fludarabine 2 durvalumab 2 ceralasertib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04188548 2025-06-04

EMBER

Eli Lilly and Company

Phase 1 Active not recruiting

BreastGynecologic

Breast Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡